These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2963586)

  • 41. Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.
    Stamatiadis D; Papaioannou MG; Giamarellos-Bourboulis EJ; Marinaki S; Giamarellou H; Stathakis CP
    Perit Dial Int; 2003; 23(2):127-31. PubMed ID: 12713078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.
    Leighton A; Gottlieb AB; Dorr MB; Jabes D; Mosconi G; VanSaders C; Mroszczak EJ; Campbell KC; Kelly E
    Antimicrob Agents Chemother; 2004 Mar; 48(3):940-5. PubMed ID: 14982787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.
    Guay DR; Awni WM; Halstenson CE; Kenny MT; Keane WF; Matzke GR
    Antimicrob Agents Chemother; 1989 Nov; 33(11):2012-5. PubMed ID: 2532874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teicoplanin: renal tolerance and pharmacokinetics in rats.
    Marre R; Schulz E; Graefe H; Sack K
    J Antimicrob Chemother; 1987 Nov; 20(5):697-704. PubMed ID: 2962975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
    Kempf P; Pompetzki H; Oppermann A; Wittenberger R; Siebert J; Fell JJ; Dieterich HA
    Infection; 1989; 17(3):177-81. PubMed ID: 2525529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
    Traina GL; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G; Bonati M
    Eur J Clin Pharmacol; 1986; 31(4):501-4. PubMed ID: 2949981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage.
    Meyer B; Traunmüller F; Hamwi A; Hollenstein UM; Locker GJ; Sperr WR; Staudinger T; Thalhammer-Scherrer R; Burgmann H; Thalhammer F
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):556-60. PubMed ID: 15516025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concentrations of teicoplanin in serum and atrial appendages of patients undergoing cardiac surgery.
    Bergeron MG; Saginur R; Desaulniers D; Trottier S; Goldstein W; Foucault P; Lessard C
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1699-702. PubMed ID: 2149493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
    Rouveix B; Jehl F; Drugeon H; Brumpt I; Caulin E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2394-9. PubMed ID: 15215086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.
    Whitehouse T; Cepeda JA; Shulman R; Aarons L; Nalda-Molina R; Tobin C; MacGowan A; Shaw S; Kibbler C; Singer M; Wilson AP
    J Antimicrob Chemother; 2005 Mar; 55(3):333-40. PubMed ID: 15705641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
    Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR
    Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin.
    Enokiya T; Muraki Y; Iwamoto T; Okuda M
    Int J Antimicrob Agents; 2015 Aug; 46(2):164-8. PubMed ID: 25982916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
    Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK
    J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.